{"commentary":{"count":3,"free_build_floor":8,"listing_floor":3,"by_channel":{"x_thread":3},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":false},"name":"AcceleRET-Lung","nct_id":"NCT04222972","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=acceleret-lung-nct04222972. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–12 commentary sources"},"registry":{"acronym":"AcceleRET-Lung","arms":[{"description":"Participants randomized to the Experimental Arm will receive Pralsetinib","label":"Pralsetinib","type":"EXPERIMENTAL"},{"description":"Participants randomized to the Active Comparator Arm will receive 1 of 6 platinum-based chemotherapy treatment regimens (with or without pembrolizumab) at the study center as chosen by the treating Investigator (based on histology)\n\nNonsquamous histology\n\n* Carboplatin or cisplatin / pemetrexed (with vitamin supplementation); with optional pemetrexed (with vitamin supplementation) maintenance.\n* Pembrolizumab / carboplatin or cisplatin / pemetrexed (with vitamin supplementation); followed by pembrolizumab and optional pemetrexed (with vitamin supplementation) maintenance.\n\nSquamous histology\n\n* Carboplatin or cisplatin / gemcitabine\n* Carboplatin with paclitaxel/nab-paclitaxel and pembrolizumab","label":"Platinum-based chemotherapy with or without pembrolizumab","type":"ACTIVE_COMPARATOR"}],"collaborators":[],"completion_date":{"date":"2025-01-27","type":"ACTUAL"},"conditions":["RET-fusion Non Small Cell Lung Cancer","Lung Neoplasm","Carcinoma, Non-Small-Cell Lung","Respiratory Tract Neoplasms","Thoracic Neoplasms","Neoplasms by Site","Neoplasms","Lung Diseases","Respiratory Tract Disease","Carcinoma, Bronchogenic","Bronchial Diseases","Head and Neck Neoplasms","Adenocarcinoma","Carcinoma","Neoplasms by Histologic Type","Neoplasms, Germ Cell and Embryonal","Neoplasms, Nerve Tissue"],"enrollment":{"count":223,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"Pralsetinib","type":"DRUG"},{"name":"Carboplatin","type":"DRUG"},{"name":"Cisplatin","type":"DRUG"},{"name":"Pemetrexed","type":"DRUG"},{"name":"Pembrolizumab","type":"DRUG"},{"name":"Gemcitabine","type":"DRUG"},{"name":"Paclitaxel","type":"DRUG"},{"name":"Nab-Paclitaxel","type":"DRUG"}],"last_update":"2026-03-05","lead_sponsor":"Hoffmann-La Roche","official_title":"A Phase III, Randomized, Open-Label Study of Pralsetinib Versus Standard of Care for First-Line Treatment of RET Fusion-Positive, Metastatic Non-Small Cell Lung Cancer","overall_status":"TERMINATED","phases":["PHASE3"],"primary_completion_date":{"date":"2025-01-27","type":"ACTUAL"},"primary_outcomes":[{"measure":"Arm A vs Arm B: Treatment Period: Progression-free Survival (PFS)","timeFrame":"Up to approximately 50 months"}],"references":[],"start_date":{"date":"2020-07-24","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Study of Pralsetinib Versus Standard of Care for First-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC)","url":"https://clinicaltrials.gov/study/NCT04222972"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/acceleret-lung-nct04222972"}